[inventory] summary of drug varieties with sales of more than 1 billion in domestic sample hospitals in recent 5 years

When we are always following up the latest research progress of drugs, stop properly and look back at the current clinical use of drugs on the market, sometimes we can have a deeper understanding of drugs Moreover, in the global scope, there is a certain "time difference" between the use of the latest drugs on the market and the use in China So how to use medicine in domestic hospitals? What kind of medicine do doctors like? It is also very important for drug research and development The author through the inquiry, summarizes the domestic sample hospital sales > 1 billion drug varieties, hope that colleagues in the process of looking at the world, do not ignore the real situation in China 1 What are the varieties with annual sales more than 1 billion? The sales performance of $1 billion can be upgraded to "blockbuster" for a drug variety In China, the sales volume can reach 1 billion RMB, which is absolutely rare According to the analysis of PDB domestic market sample hospital medication database, there were 23 varieties in 2013, 31 varieties in 2014, 36 varieties in 2015, 39 varieties in 2016, and 46 in 2017 These 46 varieties, in the order of decreasing sales, are sodium chloride, human serum albumin, clopidogrel, atorvastatin, paclitaxel, entecavir, tetrahexose monosialate ganglioside, meropenem, alprostadil, pantoprazole, oxiracetam, creatine phosphate, dizosin, lansoprazole, voriconazole, moxifloxacin, pemetrexed, human immunoglobulin , piperacillin + tazobactam (compound), amino acid (compound), cefoperazone + sulbactam (compound), docetaxel, omeprazole, propofol, thymosin α 1, rat nerve growth factor, esomeprazole, budesonide, tegafur + gemcitabine + otilacy (compound), levofloxacin, flurbiprofen, edaravone, rosuvastatin, tacrolimus Acarbose, deproteinized extract of calf blood, hemagglutinase, rituximab, butylphthalide, coenzyme A + coenzyme I (compound), thymopentin, rabeprazole, ambroxol, oxaliplatin, ribonucleic acid, alanyl glutamine Figure 1: Top 10 drug sales of sample hospitals in the domestic market in 2017 2 In recent 5 years, which "shortlisted"? Which "exits"? In 2013, there were 23 samples of more than 1 billion drugs used in hospitals, including human albumin, lansoprazole, alprostadil, monosialotetrahexosylganglioside, piperacillin + tazobactam (compound), pemetrexed, docetaxel, oxiracetam, omeprazole, calf blood deproteinized extract, levofloxacin, entecavir, amino acid (compound), ambromide Sox, sodium chloride, clopidogrel, pantoprazole, creatine phosphate, paclitaxel, thymopentin, coenzyme A + coenzyme I (compound), Ginkgo biloba extract, atorvastatin In 2014, the new varieties were propofol, human immunoglobulin, voriconazole, esomeprazole, meropenem, thymosin α 1, hemagglutinase and rat nerve growth factor; in 2015, the new varieties were edaravone, dizosin, cefoperazone + sulbactam (compound), moxixacin and acarbose; in 2016, the new varieties were budesonide, tegafur + gemcitabine + otilla Western (compound), rosuvastatin, cerebrosine and carnosine, while esomeprazole briefly jumped out of the 1 billion varieties camp; in 2017, the new varieties were alanyl glutamine, RNA, oxaliplatin, rabeprazole, butylphthalide, rituximab, tacrolimus, flurbiprofen, while esomeprazole returned to the camp, Ginkgo biloba extract, cerebrosine and carnosine jumped out of the camp Table 1: in the past five years, the sales volume of sample hospitals is more than 1 billion RMB 3 In the past five years, the author is really pleased to see the product of several varieties of rituximab that can be marked by the "1 billion camp" At the time when McAb has become popular all over the world, none of the sample hospitals in our country can enter the 1 billion mark in the past few years, which really shows the lag of Chinese citizens in drug use Fortunately, after years of efforts, rituximab finally broke the 1 billion mark of sample hospitals in 2017 For the sales of the product in the domestic sample hospitals, it mainly comes from Roche and Genentech, in which Roche has an absolute advantage [butylphthalide butylphthalide, since its listing, has been constantly praised, and continues to create good results In 2013, the sample hospital used about 430 million RMB By 2017, it has grown into an important variety of 1 billion RMB However, as an important variety of the group, the market of butylphthalide is naturally occupied by one of them, which is needless to say The sales performance of clopidogrel for this kind of cardiovascular drug close to the "magic drug" in the past five years with the sample hospital drugs of ＞ 1.5 billion RMB is no surprise In 2014, the drug use in sample hospitals exceeded 2 billion RMB Although the growth slowed down in recent years, it still reached nearly 2.4 billion in 2017 For the sales of this product, in addition to Sanofi, the original research enterprise, the leading domestic pharmaceutical enterprise naturally is Shenzhen xinlitai, and the drug use in the sample hospital has exceeded 700 million; after that, the sales of this product in Lepu pharmaceutical industry is also growing gradually, exceeding 250 million However, from the perspective of the layout of related varieties, xinlitai still has an absolute advantage in this field In recent five years, the use of dizosin in sample hospitals has been growing steadily In 2013, it was about 600 million RMB, in 2015, it exceeded 1 billion RMB, and in 2017, it reached 1.6 billion RMB, with a good momentum But for the sales of this kind of medicine by domestic enterprises, Yangzijiang pharmaceutical industry is absolutely the largest one, accounting for almost all the sales of drugs in all sample hospitals of this kind In 2017, the sales volume of Ginkgo biloba extract in the sample hospital was less than 1 billion RMB for the first time, which was between 1-1.2 billion RMB in the past five years For this variety, many domestic pharmaceutical enterprises produce and sell it, among which Dr Weima Shupei pharmaceutical factory, Heilongjiang Treasure Island pharmaceutical industry, Shenwei pharmaceutical industry and yuekang pharmaceutical industry are relatively ahead in product sales, and the drugs used in sample hospitals are more than 100 million RMB 4 Summary and Prospect In the past five years, we found that the number of varieties of drugs used in sample hospitals is increasing in recent years, which reflects the vitality of China's pharmaceutical market; the monoclonal antibody family has finally broken the 1 billion mark, which proves that the gap between China's national drug use and other developed countries in the world is gradually narrowing; the 1 billion family drug varieties and members are also increasing The good embodiment of the improvement of quality proves that China's pharmaceutical market is increasingly on the right track However, there are still some shortcomings, such as the more excellent macromolecular drugs, which are still relatively lacking, and the Tinian anti-cancer drugs have not been better "power" But on the whole, the real "good medicine" is being used more and better Data source: Pharmaceutical intelligence data, PDB database